Biblioscape User Community

We are now using Elsevier's EMBASE.com database instead of EMBASE through OVID. Is there a filter for this online database (it is closed access to those without a subscription)? If not, could one be made?

I've included two records at the bottom as text to give you an idea of how we need to download their articles.

Thank you,

Julia DeLuca

 RECORD 1
TITLE
  "Virostatics" as a potential new class of HIV drugs
AUTHOR NAMES
  Kelly L.M.
  Lisziewicz J.
  Lori F.
AUTHOR NAME AND ADDRESS
  F. Lori. RIGHT, 2233 Wisconsin Ave., Washington, DC 20007, United States.
E-mail: rightpv@tin.it
SOURCE
  Current Pharmaceutical Design (2004) 10:32 (4103-4120)
ISSN
  1381-6128
ABSTRACT
  The combination of three or more antiretroviral drugs is referred to as
highly active antiretroviral therapy (HAART) and constitutes the standard
of care for HIV-1 patients in industrialized nations. Although HAART is
usually effective in reducing viral load and re-constituting CD4 counts,
latent virus reservoirs persist, and as many as 60 years therapy [1, 2] may
be required to eradicate the virus. Meanwhile, patients are likely to
experience drug related toxicity and may have to change therapy due to the
emergence of drug resistant strains. For these reasons, the search for
different therapeutic approaches continues. A new concept of
antiviral/cytostatic ("virostatics") drugs has been proposed within the
context of HAART to restrict virus target populations (CD4(+) T
lymphocytes), target viral reservoirs, and possibly restore immune
functions, by reducing excess immune activation, a fundamental component of
HIV/AIDS pathogenesis. These virostatics include drugs such as hydroxyurea,
mycophenolic acid, leflunomide and rapamycin, which are currently used for
other therapeutic indications; and other experimental drugs, which are not
for human use. They utilize multiple novel mechanisms of action to impede
HIV by targeting host cellular proteins that are not susceptible to
mutation. Therefore, their resistance profile appears to be quite
favorable. Since many of these drugs act by inhibiting the synthesis of
deoxynucleotides, essential for HPV reverse transcription, they favor the
incorporation of nucleoside analogues into viral DNA, thus synergizing with
the antiviral activity of currently used nucleoside reverse transcriptase
inhibitors (NRTI). The rationale for the use of virostatics in HIV/AIDS,
their mechanism of action, and ongoing preclinical and clinical research
will be reviewed. (copyright) 2004 Bentham Science Publishers Ltd.
EMTREE DRUG INDEX TERMS (MAJOR FOCUS)
  antivirus agent (adverse drug reaction)
  antivirus agent (clinical trial)
  antivirus agent (drug combination)
  antivirus agent (drug comparison)
  antivirus agent (drug dose)
  antivirus agent (drug interaction)
  antivirus agent (drug therapy)
  antivirus agent (pharmacology)
EMTREE DRUG INDEX TERMS
  RNA directed DNA polymerase inhibitor (adverse drug reaction)
  RNA directed DNA polymerase inhibitor (clinical trial)
  RNA directed DNA polymerase inhibitor (drug combination)
  RNA directed DNA polymerase inhibitor (drug comparison)
  RNA directed DNA polymerase inhibitor (drug concentration)
  RNA directed DNA polymerase inhibitor (drug dose)
  RNA directed DNA polymerase inhibitor (drug interaction)
  RNA directed DNA polymerase inhibitor (drug therapy)
  RNA directed DNA polymerase inhibitor (oral drug administration)
  RNA directed DNA polymerase inhibitor (pharmacology)
  a 77 1726
  abacavir (clinical trial)
  abacavir (drug combination)
  abacavir (drug interaction)
  abacavir (drug therapy)
  abacavir (pharmacology)
  amprenavir (clinical trial)
  amprenavir (drug combination)
  amprenavir (drug therapy)
  aphidicolin (drug development)
  aphidicolin (pharmacology)
  butyric acid (pharmacokinetics)
  butyric acid (pharmacology)
  cytostatic agent (drug comparison)
  cytostatic agent (drug therapy)
  cytostatic agent (pharmacology)
  demecolcine (pharmacology)
  deoxyribonucleotide (endogenous compound)
  didanosine (adverse drug reaction)
  didanosine (clinical trial)
  didanosine (drug combination)
  didanosine (drug comparison)
  didanosine (drug concentration)
  didanosine (drug dose)
  didanosine (drug interaction)
  didanosine (drug therapy)
  didanosine (oral drug administration)
  didanosine (pharmacology)
  histone deacetylase (endogenous compound)
  hydroxyurea (adverse drug reaction)
  hydroxyurea (clinical trial)
  hydroxyurea (drug combination)
  hydroxyurea (drug comparison)
  hydroxyurea (drug dose)
  hydroxyurea (drug interaction)
  hydroxyurea (drug therapy)
  hydroxyurea (pharmacology)
  immunosuppressive agent (adverse drug reaction)
  immunosuppressive agent (clinical trial)
  immunosuppressive agent (drug combination)
  immunosuppressive agent (drug therapy)
  indinavir (adverse drug reaction)
  indinavir (clinical trial)
  indinavir (drug comparison)
  indinavir (drug therapy)
  indinavir (pharmacology)
  lamivudine (clinical trial)
  lamivudine (drug combination)
  lamivudine (drug comparison)
  lamivudine (drug therapy)
  lamivudine (pharmacology)
  leflunomide (adverse drug reaction)
  leflunomide (clinical trial)
  leflunomide (drug combination)
  leflunomide (drug dose)
  leflunomide (pharmacokinetics)
  leflunomide (pharmacology)
  mycophenolic acid 2 morpholinoethyl ester (adverse drug reaction)
  mycophenolic acid 2 morpholinoethyl ester (clinical trial)
  mycophenolic acid 2 morpholinoethyl ester (drug combination)
  mycophenolic acid 2 morpholinoethyl ester (drug comparison)
  mycophenolic acid 2 morpholinoethyl ester (drug dose)
  mycophenolic acid 2 morpholinoethyl ester (drug interaction)
  mycophenolic acid 2 morpholinoethyl ester (drug therapy)
  mycophenolic acid 2 morpholinoethyl ester (intraperitoneal drug
administration)
  mycophenolic acid 2 morpholinoethyl ester (pharmacology)
  mycophenolic acid (adverse drug reaction)
  mycophenolic acid (clinical trial)
  mycophenolic acid (drug combination)
  mycophenolic acid (drug comparison)
  mycophenolic acid (drug dose)
  mycophenolic acid (drug interaction)
  mycophenolic acid (drug therapy)
  mycophenolic acid (intraperitoneal drug administration)
  mycophenolic acid (pharmacology)
  nocodazole (pharmacology)
  olomoucine (drug comparison)
  olomoucine (pharmacology)
  rapamycin (adverse drug reaction)
  rapamycin (drug therapy)
  rapamycin (pharmacology)
  resveratrol (pharmacology)
  roscovitine (drug comparison)
  roscovitine (pharmacology)
  stavudine (adverse drug reaction)
  stavudine (clinical trial)
  stavudine (drug combination)
  stavudine (drug comparison)
  stavudine (drug interaction)
  stavudine (drug therapy)
  stavudine (pharmacology)
  stress activated protein kinase (endogenous compound)
  tenofovir (drug combination)
  tenofovir (drug therapy)
  tenofovir (pharmacology)
  teriflunomide (adverse drug reaction)
  teriflunomide (clinical trial)
  teriflunomide (drug dose)
  teriflunomide (pharmacokinetics)
  teriflunomide (pharmacology)
  unindexed drug
  zalcitabine (drug combination)
  zalcitabine (drug comparison)
  zalcitabine (drug interaction)
  zalcitabine (pharmacology)
  zidovudine (adverse drug reaction)
  zidovudine (drug combination)
  zidovudine (drug comparison)
  zidovudine (drug interaction)
  zidovudine (drug therapy)
  zidovudine (pharmacology)
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Human immunodeficiency virus infection (drug resistance)
  Human immunodeficiency virus infection (drug therapy)
  Human immunodeficiency virus infection (etiology)
  Human immunodeficiency virus infection (prevention)
EMTREE MEDICAL INDEX TERMS
  Human immunodeficiency virus
  Stevens Johnson syndrome (side effect)
  acne (side effect)
  acquired immune deficiency syndrome (drug therapy)
  acquired immune deficiency syndrome (etiology)
  agranulocytosis (side effect)
  alopecia (side effect)
  anemia (side effect)
  anorexia (side effect)
  antiviral activity
  bone marrow suppression (side effect)
  clinical trial
  cytomegalovirus infection (side effect)
  diarrhea (side effect)
  dizziness (side effect)
  drug blood level
  drug eruption (side effect)
  drug fatality (side effect)
  drug indication
  drug mechanism
  drug potentiation
  erythema (side effect)
  gastrointestinal hemorrhage (side effect)
  gastrointestinal symptom (side effect)
  graft rejection (complication)
  graft rejection (drug therapy)
  graft rejection (prevention)
  highly active antiretroviral therapy
  host cell
  human
  hypercholesterolemia (side effect)
  hyperpigmentation (side effect)
  hypertension (side effect)
  hypertriglyceridemia (side effect)
  immunomodulation
  infection risk
  kidney dysfunction (side effect)
  leg ulcer (side effect)
  leukopenia (side effect)
  liver disease (side effect)
  liver dysfunction (side effect)
  liver injury (side effect)
  liver toxicity (side effect)
  lung edema (side effect)
  lymphocyte count
  lymphoma (side effect)
  malignant neoplastic disease (side effect)
  metabolic disorder (side effect)
  mitochondrial toxicity (side effect)
  monotherapy
  nausea (side effect)
  neutropenia (side effect)
  obesity (side effect)
  pancreatitis (side effect)
  pancytopenia (side effect)
  pathogenesis
  patient care
  pneumonia (side effect)
  priority journal
  pruritus (side effect)
  pyrimidine synthesis
  reverse transcription
  review
  sepsis (side effect)
  side effect (side effect)
  skin cancer (side effect)
  skin toxicity (side effect)
  teratogenicity (side effect)
  thrombocytopenia (side effect)
  toxic epidermal necrolysis (side effect)
  virus infection (side effect)
  virus load
  virus mutation
  virus replication
  virus resistance
  virus strain
  vomiting (side effect)
  weight reduction
DRUG TRADE NAMES
  cellcept
  arava
  a 77 1726
CAS REGISTRY NUMBERS
  hydroxyurea (127-07-1)
  mycophenolic acid (23047-11-2, 24280-93-1)
  leflunomide (75706-12-6)
  rapamycin (53123-88-9)
  resveratrol (501-36-0)
  abacavir (136470-78-5, 188062-50-2)
  didanosine (69655-05-6)
  zidovudine (30516-87-1)
  lamivudine (134678-17-4, 134680-32-3)
  stavudine (3056-17-5)
  indinavir (150378-17-9, 157810-81-6, 180683-37-8)
  mycophenolic acid 2 morpholinoethyl ester (116680-01-4, 128794-94-5)
  zalcitabine (7481-89-2)
  tenofovir (147127-19-3, 147127-20-6)
  amprenavir (161814-49-9)
  teriflunomide (108605-62-5)
  aphidicolin (38966-21-1)
  butyric acid (107-92-6, 156-54-7, 461-55-2)
  roscovitine (186692-46-6)
  olomoucine (101622-51-9)
  nocodazole (31430-18-9)
  demecolcine (477-30-5)
  histone deacetylase (9076-57-7)
  stress activated protein kinase (155215-87-5)
EMBASE CLASSIFICATIONS
  Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
  General Pathology and Pathological Anatomy (5)
  Immunology, Serology and Transplantation (26)
  Clinical and Experimental Pharmacology (30)
  Drug Literature Index (37)
  Adverse Reactions Titles (38)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004534949
COPYRIGHT
  Copyright 2005 Elsevier B.V., All rights reserved.

RECORD 2
TITLE
  The process of seeking sex partners online and implications for STD/HIV
prevention
AUTHOR NAMES
  Bull S.S.
  McFarlane M.
  Lloyd L.
  Rietmeijer C.
AUTHOR NAME AND ADDRESS
  S.S. Bull. Colorado Health Outcomes Program, Univ. of Colorado Hlth. Sci.
Center, Mail Stop f-443, PO Box 6508, Aurora, CO 80045-0508, United States.
E-mail: sheana.bull@uchsc.edu
SOURCE
  AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV (2004) 16:8
(1012-1020). Date of Publication: Nov 2004
ISSN
  0954-0121
ABSTRACT
  Research has shown that online sex-seeking among men who have sex with men
(MSM) is related to elevated risk for sexually transmitted diseases (STDs),
including HIV infection; however, the process of seeking sex online is not
well understood. It is important to understand the process of seeking sex
partners in order to determine the best method for reaching MSM at high
risk for infection. We report on baseline data from the Smart Sex Quest, an
Internet-based STD prevention intervention targeting MSM (n = 1,776, 79%
white, mean age = 33 years). Results indicate that older, white,
college-educated men solicited sex partners on AOL, whereas Gay.com was a
more frequent choice among younger men. Yahoo was named as a solicitation
site more frequently by those with no college education, as were 'bareback'
websites devoted to facilitating anal sex without the use of condoms.
Following online solicitation, men tended to meet in public restrooms
(86%), partners' homes (74%) and their own home (57%). Though results are
limited by the self-selected nature of the sample, the data have important
implications for online outreach, study recruitment and intervention.
EMTREE MEDICAL INDEX TERMS (MAJOR FOCUS)
  Human immunodeficiency virus infection (prevention)
  human relation
  infection prevention
  sexuality
  sexually transmitted disease (prevention)
EMTREE MEDICAL INDEX TERMS
  adult
  age distribution
  condom
  conference paper
  controlled study
  education
  health program
  health promotion
  high risk population
  homosexuality
  human
  infection risk
  male
  normal human
  online system
  priority journal
  race difference
  risk assessment
  safe sex
  sample size
EMBASE CLASSIFICATIONS
  Microbiology: Bacteriology, Mycology, Parasitology and Virology (4)
  Public Health, Social Medicine and Epidemiology (17)
  Biophysics, Bioengineering and Medical Instrumentation (27)
LANGUAGE OF ARTICLE
  English
LANGUAGE OF SUMMARY
  English
EMBASE ACCESSION NUMBER
  2004534213
COPYRIGHT
  Copyright 2004 Elsevier B.V., All rights reserved.